Anzeige
Mehr »
Samstag, 11.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
10.10.25 | 17:01
27,180 Euro
-0,15 % -0,040
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
26,82027,10010.10.
26,84027,12010.10.

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSwedish Orphan Biovitrum AB: Invitation: Sobi's Q3 2025 report204STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Sobi plans to publish its report for the third quarter of 2025 on 23 October 2025 at 08:00 CEST. Investors, analysts, and the media are...
► Artikel lesen
02.10.Kinaxis Inc.: Sobi setzt auf Kinaxis, um den Zugang zu lebensverändernden Behandlungen zu beschleunigen278Durch die Verbindung von KI-gestützter Lieferkettenkoordination und Innovationen im Bereich seltener Krankheiten werden wichtige Therapien für Patienten, die diese benötigen, schneller bereitgestellt...
► Artikel lesen
02.10.Kinaxis Inc: Kinaxis Maestro selected by Swedish Orphan Biovitrum10
02.10.Kinaxis Inc.: Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments254AI-powered supply chain orchestration and rare-disease innovation join forces for faster delivery of critical therapies to patients in need Kinaxis (TSX:KXS), a global leader in end-to-end supply...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
30.09.Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi190STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are...
► Artikel lesen
23.09.Sobi surpasses Roche in rare disease patient groups' reputation rankings29
22.09.Ionis and Sobi's Tryngolza gains approval in EU for FCS treatment7
19.09.KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs3
19.09.Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome1
19.09.EU approves Ionis and Sobi's FCS treatment Tryngolza4
19.09.Swedish Orphan Biovitrum AB: Tryngolza (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)334STOCKHOLM, Sept. 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals...
► Artikel lesen
19.09.SWEDISH ORPHAN BIOVITRUM AB: Tryngolza (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)3
10.09.Swedish Orphan Biovitrum AB: Invitation: Sobi's NASP and Uncontrolled Gout call and webcast265NASP (previously known as SEL-212) - clinical program overview and uncontrolled gout disease landscape. STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Investors, analysts, and members of...
► Artikel lesen
10.09.Swedish Orphan Biovitrum AB: FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout394Submission includes results of the pivotal DISSOLVE I and II studiesNASP PDUFA date set for 27 June 2026STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical...
► Artikel lesen
29.08.Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi310STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049...
► Artikel lesen
21.08.Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares245STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class...
► Artikel lesen
25.07.Ionis Pharma, Sobi Get Positive CHMP Opinion For TRYNGOLZA In Familial Chylomicronemia Syndrome17
25.07.Sobi North America Announces Approval Of Doptelet For Pediatric ITP476STOCKHOLM (dpa-AFX) - Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the FDA approved Doptelet or avatrombopag for the treatment of thrombocytopenia...
► Artikel lesen
25.07.Swedish Orphan Biovitrum AB: TRYNGOLZA (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)468Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission...
► Artikel lesen
25.07.Sobi, Inc.: Sobi Announces U.S. Food and Drug Administration Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia ...198Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
► Artikel lesen
Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1